Hikal posted revenue of INR 5,145mn with 11.1% YoY growth which was 8.7% above our estimate of INR 4733mn driven by the strong growth in the crop protection segment. On segmental performance: The crop protection segment grew by 27% (YoY) to INR 2464mn on the back of Increased sales volume of CDMO products and favourable price increases for certain products. Pharmaceutical segment revenue remained flat at INR 2,682mn on account of slower offtake by several customers due to the higher price of products led by rising input costs. Management expects raw material challenges to continue in the next few months and is working with their suppliers and customers to mitigate the price fluctuations. Higher operational cost combined with flat revenues resulted in a...